-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Current treatment options for patients with advanced hepatocellular carcinoma (HCC) remain limited
On August 23, 2022, Wang Cun, Qin Wenxin of Shanghai Jiao Tong University and René Bernards of Shanghai Jiao Tong University/Netherlands Cancer Institute joint newsletter published a research paper entitled "EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma" in The Journal of Cell Discovery (IF=38).
In a recent study, EGFR inhibitors were also found to enhance their efficacy
Current treatment options for patients with advanced hepatocellular carcinoma (HCC) remain limited
—END—
The content is [iNature]